Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
GCN2iB is an inhibitor of general control nonderepressible 2 kinase (GCN2; IC50 = 2.4 nM).1 It is selective for GCN2 over a panel of 465 kinases but does inhibit MAP2K5, eukaryotic translation initiation factor 2α kinase 2 (EIF2AK2), and MAP3K20 at 1 µM. GCN2iB (1 µM), in combination with L-aspariginase, reduces the viability of mouse embryonic fibroblasts (MEFs). It decreases the levels of activating transcription factor 4 (ATF4) and phosphorylated GCN2 in combination with L-aspariginase in CCRF CEM leukemia cells when used at a concentration of 0.4 µM. In vivo, GCN2iB (10 mg/kg twice per day), in combination with L-aspariginase, reduces tumor volume in CCRF CEM and MV4-11 leukemia mouse xenograft models.
WARNING This product is not for human or veterinary use.
1. Inhibition of GCN2 sensitizes ASNS-